12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Secukinumab: Phase III data

The double-blind, international Phase III FIXTURE trial in 1,307 patients with moderate to severe chronic plaque psoriasis showed that subcutaneous secukinumab met the co-primary endpoints of improving PASI 75 and IGA response rates at week 12 vs. placebo. Secukinumab also met the secondary endpoints of improving PASI 75 and IGA response rates at week 12 vs. Enbrel etanercept. Novartis...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >